Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Malignant Lymphoma

  Free Subscription


Articles published in Bone Marrow Transplant

Retrieve available abstracts of 68 articles:
HTML format
Text format



Single Articles


    February 2018
  1. AVIVI I, Boumendil A, Finel H, Nagler A, et al
    Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2018 Feb 20. pii: 10.1038/s41409-017-0063.
    PubMed     Text format     Abstract available


  2. MARCHESI F, Capria S, Giannarelli D, Trisolini SM, et al
    BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.
    Bone Marrow Transplant. 2018 Feb 13. pii: 10.1038/s41409-018-0120.
    PubMed     Text format    


  3. CASTAGNA L, Boubdallah R, Furst S, Coso D, et al
    Corrigendum: Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT.
    Bone Marrow Transplant. 2018;53:234.
    PubMed     Text format     Abstract available


    January 2018
  4. FUJI S, Kurosawa S, Inamoto Y, Murata T, et al
    Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma: a decision analysis.
    Bone Marrow Transplant. 2018 Jan 25. pii: 10.1038/s41409-017-0082.
    PubMed     Text format    


  5. JIMENEZ-UBIETO A, Grande C, Caballero D, Yanez L, et al
    Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry.
    Bone Marrow Transplant. 2018 Jan 23. pii: 10.1038/s41409-018-0096.
    PubMed     Text format    


  6. LAHOUD OB, Moskowitz AJ, Horwitz SM, Giralt SA, et al
    Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2018 Jan 22. pii: 10.1038/s41409-017-0086.
    PubMed     Text format    


  7. ROBINSON SP, Boumendil A, Finel H, Peggs KS, et al
    Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.
    Bone Marrow Transplant. 2018 Jan 15. pii: 10.1038/s41409-017-0067.
    PubMed     Text format     Abstract available


  8. GAUTHIER J, Poire X, Gac AC, Leclerc M, et al
    Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2018 Jan 12. pii: 10.1038/s41409-017-0018.
    PubMed     Text format     Abstract available


    December 2017
  9. FALCONE U, Jiang H, Bashir S, Tsang R, et al
    Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0054.
    PubMed     Text format    


  10. MARIOTTI J, Bramanti S, Devillier R, Furst S, et al
    Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Dec 21. pii: 10.1038/s41409-017-0032.
    PubMed     Text format    


  11. MOHTY M, Azar N, Chabannon C, Le Gouill S, et al
    Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.
    Bone Marrow Transplant. 2017 Dec 18. pii: 10.1038/s41409-017-0033.
    PubMed     Text format     Abstract available


    October 2017
  12. JOFFE E, Rosenberg D, Rozovski U, Perry C, et al
    Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin's and non-Hodgkin's B-cell lymphoma.
    Bone Marrow Transplant. 2017 Oct 16. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  13. KANSAGRA A, Inwards DJ, Ansell SM, Micallef IN, et al
    Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation.
    Bone Marrow Transplant. 2017 Oct 16. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  14. RE A, Gini G, Rupolo M, Levis A, et al
    Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk.
    Bone Marrow Transplant. 2017 Oct 9. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  15. GALIENI P, Troiani E, Bigazzi C, Mazzotta S, et al
    Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2017 Oct 2. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  16. RIEDELL PA, Bishop MR
    Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.
    Bone Marrow Transplant. 2017 Oct 2. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    July 2017
  17. DAMLAJ M, Ghazi S, Syed G, Pasha T, et al
    Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Jul 10. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    June 2017
  18. KASSAM S, Chernucha E, O'Neill A, Hemmaway C, et al
    High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  19. GIACCONE L, Festuccia M, Zallio F, Sorasio R, et al
    Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    May 2017
  20. BENTO L, Boumendil A, Finel H, Le Gouill S, et al
    Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.
    Bone Marrow Transplant. 2017 May 22. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  21. CASTAGNA L, Bramanti S, Devillier R, Sarina B, et al
    Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.
    Bone Marrow Transplant. 2017;52:797.
    PubMed     Text format    


    April 2017
  22. SCHORB E, Fox CP, Fritsch K, Isbell L, et al
    High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.
    Bone Marrow Transplant. 2017 Apr 24. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


  23. EL CHEIKH J, Massoud R, Abudalle I, Haffar B, et al
    Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Apr 10. doi: 10.1038/bmt.2017.
    PubMed     Text format    


  24. YAMASAKI S, Suzuki R, Hatano K, Fukushima K, et al
    Therapy-related acute myeloid leukemia and myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format     Abstract available


    January 2017
  25. HEGEROVA L, Cao Q, Lazaryan A, McClune BL, et al
    Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era.
    Bone Marrow Transplant. 2017 Jan 30. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  26. DAMAJ G, Cornillon J, Bouabdallah K, Gressin R, et al
    Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.
    Bone Marrow Transplant. 2017 Jan 23. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  27. RADFORD J, McKay P, Malladi R, Johnson R, et al
    Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation.
    Bone Marrow Transplant. 2017 Jan 16. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  28. CASTAGNA L, Bramanti S, Devillier R, Sarina B, et al
    Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.
    Bone Marrow Transplant. 2017 Jan 16. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  29. FAIR C, Shanley R, Rogosheske J, Lazaryan A, et al
    BEAM conditioning is well-tolerated and yields similar survival in obese and non-obese patients with lymphoma: no requirement for weight-based dose modifications.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  30. FUJIWARA H, Fuji S, Wake A, Kato K, et al
    Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  31. GAUTHIER J, Castagna L, Garnier F, Guillaume T, et al
    Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  32. HAVERKOS BM, Huang Y, Elder P, O'Donnell L, et al
    A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    December 2016
  33. STENEHJEM JS, Smeland KB, Murbraech K, Holte H, et al
    Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.
    Bone Marrow Transplant. 2016 Dec 19. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  34. MEISSNER J, Finel H, Dietrich S, Boumendil A, et al
    Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience.
    Bone Marrow Transplant. 2016 Dec 19. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    November 2016
  35. SHAH N, Rauenzahn S, Veltri L, Wen S, et al
    Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL).
    Bone Marrow Transplant. 2016 Nov 28. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  36. GHEZ D, Fortpied C, Mounier N, Carde P, et al
    First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.
    Bone Marrow Transplant. 2016 Nov 28. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  37. ROBINSON SP
    Diffuse large B-cell lymphoma: the challenge of relapse after an autologous stem cell transplant.
    Bone Marrow Transplant. 2016 Nov 21. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    October 2016
  38. POLISTENA P, Tran Q, Cirillo M, O'Sullivan M, et al
    Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma.
    Bone Marrow Transplant. 2016 Oct 31. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  39. GAUTHIER J, Holmberg L, Wu D, Bensinger W, et al
    Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas.
    Bone Marrow Transplant. 2016 Oct 24. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  40. CASTAGNA L, Sarina B, Crocchiolo R, Bramanti S, et al
    Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 Oct 17. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    September 2016
  41. BAI L, Peters L, Xia W, Best G, et al
    Assessing pilot vial material as a surrogate for functional and phenotypic stem cell markers in cryopreserved haematopoietic stem cell product.
    Bone Marrow Transplant. 2016 Sep 26. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  42. VAN DEN NESTE E, Schmitz N, Mounier N, Gill D, et al
    Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.
    Bone Marrow Transplant. 2016 Sep 19. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  43. PHILLIPS EH, Hodson A, Hermine O, Bazarbachi A, et al
    Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?
    Bone Marrow Transplant. 2016 Sep 12. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  44. RAMASWAMI R, Pria AD, Parker K, McCann S, et al
    Outcomes of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory HIV-associated lymphoma.
    Bone Marrow Transplant. 2016 Sep 5. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    July 2016
  45. CAGDAS D, Erman B, Hanoglu D, Tavil B, et al
    Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other.
    Bone Marrow Transplant. 2016 Jul 25. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  46. EHRLICH KB, Miller GE, Scheide T, Baveja S, et al
    Pre-transplant emotional support is associated with longer survival after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2016 Jul 18. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    June 2016
  47. LINK CS, Mies F, Scheele J, Kramer M, et al
    Long-term follow-up of patients with relapsed or refractory non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 Jun 13. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    May 2016
  48. KOTHARI J, Foley M, Peggs KS, Mackenzie S, et al
    A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.
    Bone Marrow Transplant. 2016 May 23. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  49. TSIRIGOTIS P, Danylesko I, Gkirkas K, Shem-Tov N, et al
    Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 May 16. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  50. GAYOSO J, Balsalobre P, Pascual MJ, Castilla-Llorente C, et al
    Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.
    Bone Marrow Transplant. 2016 May 9. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  51. BEIER R, Sykora KW, Woessmann W, Maecker-Kolhoff B, et al
    Allogeneic-matched sibling stem cell transplantation in a 13-year-old boy with ataxia telangiectasia and EBV-positive non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2016 May 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    April 2016
  52. SINGH AK, Porrata LF, Aljitawi O, Lin T, et al
    Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma.
    Bone Marrow Transplant. 2016 Apr 25. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  53. HONG S, Rybicki L, Abounader DM, Bolwell BJ, et al
    Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma.
    Bone Marrow Transplant. 2016 Apr 25. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  54. TESSOULIN B, Ceballos P, Chevallier P, Blaise D, et al
    Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.
    Bone Marrow Transplant. 2016 Apr 25. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


  55. HOCHBERG J, Harrison L, Morris E, Militano O, et al
    Safety of liposomal cytarabine CNS prophylaxis in children, adolescent and young adult hematopoietic stem cell transplant recipients with acute leukemia and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2016 Apr 18. doi: 10.1038/bmt.2016.
    PubMed     Text format    


  56. STAMATOULLAS A, Brice P, Gueye MS, Mareschal S, et al
    Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).
    Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.
    PubMed     Text format     Abstract available


    March 2016
  57. VARMA A, Saliba RM, Torres HA, Afrough A, et al
    Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation.
    Bone Marrow Transplant. 2016 Mar 7. doi: 10.1038/bmt.2016.
    PubMed     Text format    


    February 2016
  58. YARED JA, Hardy N, Singh Z, Hajj S, et al
    Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 Feb 1. doi: 10.1038/bmt.2015.
    PubMed     Text format    


  59. NELSON AA, Harrington AM, Kroft S, Dahar MA, et al
    Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer.
    Bone Marrow Transplant. 2016;51:300-2.
    PubMed     Text format    


    January 2016
  60. RASHIDI A, Ebadi M, Cashen AF
    Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2016 Jan 4. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


    November 2015
  61. ROBINSON SP, Boumendil A, Finel H, Blaise D, et al
    Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.
    Bone Marrow Transplant. 2015 Nov 30. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  62. MAMEZ AC, Levy V, Chevallier P, Blaise D, et al
    Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
    Bone Marrow Transplant. 2015 Nov 23. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


  63. SELLNER L, Boumendil A, Finel H, Choquet S, et al
    Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
    Bone Marrow Transplant. 2015 Nov 16. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


    September 2015
  64. HAIK L, Beylot-Barry M, Vigouroux S, Tabrizi R, et al
    Sirolimus-related anal ulceration in a female patient after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2015 Sep 14. doi: 10.1038/bmt.2015.
    PubMed     Text format    


    August 2015
  65. YERUSHALMI R, Shem-Tov N, Danylesko I, Avigdor A, et al
    Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.
    Bone Marrow Transplant. 2015 Aug 3. doi: 10.1038/bmt.2015.
    PubMed     Text format     Abstract available


    June 2015
  66. GARCIAZ S, Castagna L, Bouabdallah R, Furst S, et al
    Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available.
    Bone Marrow Transplant. 2015;50:865-7.
    PubMed     Text format    


    May 2015
  67. BERGER NA
    A time to stop, a time to start: high-dose chemotherapy in overweight and obese patients.
    Bone Marrow Transplant. 2015;50:617-8.
    PubMed     Text format    


    March 2015
  68. HONG S, Le-Rademacher J, Artz A, McCarthy PL, et al
    Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders.
    Bone Marrow Transplant. 2015;50:367-74.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: